Health knowledge made personal
Join this community!
› Share page:
Search posts:

PSM Peptides as Vaccine Targets Against Methicillin-Resistant Staphylococcus aureus

Posted Aug 31 2011 8:00pm

Description of Invention:
Available for licensing and commercial development are compositions and methods for the treatment and inhibition of Methicillin-resistant Staphylococcus aureus (MRSA), a dangerous human pathogen. The invention concerns immunogenic peptides that can be used to induce protective immunity against MRSA, including phenol-soluble modulin (PSM) peptides.

In addition to the MRSA infections that occur in immunocompromised patients in hospitals, new MRSA strains have recently emerged that can cause severe infections (such as necrotizing fasciitis) or death in otherwise healthy adults. These strains are increasingly involved in community-associated (CA)-MRSA infections, and can be contracted outside of the health care settings. The incidence of CA-MRSA infections is increasing and the majority of infections in patients reporting to emergency departments in the US is now due to CA-MRSA.

The invention describes a class of secreted staphylococcal peptides with an extraordinary ability to recruit, activate, and subsequently lyse human neutrophils, thus eliminating the main cellular defense against S. aureus infection. The peptides are encoded by the PSM gene cluster and include PSMalpha1, PSMalpha2, PSMalpha3, and PSMalpha4, all of which activate and subsequently lyse neutrophils. These peptides are produced at especially high levels in CA-MRSA and to a large extent determine their aggressive behavior and ability to cause disease in animal models of infection. Thus, the peptides represent a set of virulence factors of S. aureus that account for the enhanced virulence of CA-MRSA. The identification of these peptides enables the production of vaccines and other preventative and/or therapeutic agents for use in subjects infected with MRSA.

Development of new classes of antibiotics and vaccines against Methicillin-resistant Staphylococcus aureus infections.

Development Status:
Early stage

Rong Wang (NIAID)
Michael Otto (NIAID)

Patent Status:
HHS, Reference No. E-239-2007/3
US, Application No. 12/631,253 filed 04 Dec 2009

Relevant Publication:
  1. Wang R, et al. [ PMID 17994102 ]

Collaborative Research Opportunity:
The NIAID Laboratory of Human Bacterial Pathogenesis is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Please contact William Ronnenberg at 301-451-3522 or for more information.

For Licensing Information Please Contact:
Edward (Tedd) Fenn
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Phone: 301-435-5031
Fax: 301-402-0220

Ref No: 1717

Updated: 09/2011

Post a comment
Write a comment:

Related Searches